Free Stock Analysis Report: Buy Sell Hold Predictions on Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyze Any Stock Free
Andrea  Sabens net worth and biography

Andrea Sabens Biography and Net Worth

CAO of Lantheus
Ms. Andrea Sabens is a Chief Accounting Officer at Lantheus Holdings, Inc. She received her undergraduate degree from the University of New Hampshire, a graduate degree from Southern New Hampshire University and an MBA from Southern New Hampshire University.

What is Andrea Sabens' net worth?

The estimated net worth of Andrea Sabens is at least $3.69 million as of July 19th, 2023. Ms. Sabens owns 59,767 shares of Lantheus stock worth more than $3,694,796 as of September 24th. This net worth evaluation does not reflect any other investments that Ms. Sabens may own. Learn More about Andrea Sabens' net worth.

How old is Andrea Sabens?

Ms. Sabens is currently 44 years old. There are 7 older executives and no younger executives at Lantheus. The oldest executive at Lantheus is Ms. Mary Anne Heino, CEO & Director, who is 63 years old. Learn More on Andrea Sabens' age.

How do I contact Andrea Sabens?

The corporate mailing address for Ms. Sabens and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Andrea Sabens' contact information.

Has Andrea Sabens been buying or selling shares of Lantheus?

During the past quarter, Andrea Sabens has sold $159,204.24 in shares of Lantheus stock. Most recently, Andrea Sabens sold 1,752 shares of the business's stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $90.87, for a transaction totalling $159,204.24. Following the completion of the sale, the chief accounting officer now directly owns 59,767 shares of the company's stock, valued at $5,431,027.29. Learn More on Andrea Sabens' trading history.

Who are Lantheus' active insiders?

Lantheus' insider roster includes Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.

Are insiders buying or selling shares of Lantheus?

During the last year, insiders at the medical equipment provider sold shares 34 times. They sold a total of 303,168 shares worth more than $22,856,397.09. The most recent insider tranaction occured on September, 15th when insider Daniel Niedzwiecki sold 2,846 shares worth more than $189,059.78. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.

Information on this page was last updated on 9/15/2023.

Andrea Sabens Insider Trading History at Lantheus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2023Sell1,752$90.87$159,204.2459,767View SEC Filing Icon  
5/15/2023Sell385$99.36$38,253.6061,519View SEC Filing Icon  
4/17/2023Sell386$88.67$34,226.6261,904View SEC Filing Icon  
3/15/2023Sell386$71.58$27,629.8862,290View SEC Filing Icon  
3/6/2023Sell7,705$72.56$559,074.8063,626View SEC Filing Icon  
1/17/2023Sell386$52.97$20,446.4260,846View SEC Filing Icon  
12/15/2022Sell386$53.75$20,747.5061,232View SEC Filing Icon  
10/17/2022Sell386$70.50$27,213.0062,004View SEC Filing Icon  
9/15/2022Sell386$85.83$33,130.3862,390View SEC Filing Icon  
8/15/2022Sell386$82.82$31,968.5262,776View SEC Filing Icon  
7/18/2022Sell1,093$71.47$78,116.7163,162View SEC Filing Icon  
7/15/2022Sell386$69.12$26,680.3264,255View SEC Filing Icon  
6/15/2022Sell386$62.87$24,267.8264,441View SEC Filing Icon  
3/1/2022Sell2,409$48.04$115,728.36View SEC Filing Icon  
1/18/2022Sell1,242$26.93$33,447.06View SEC Filing Icon  
12/15/2021Sell1,242$26.72$33,186.24View SEC Filing Icon  
11/15/2021Sell1,242$30.47$37,843.74View SEC Filing Icon  
10/15/2021Sell1,242$23.71$29,447.82View SEC Filing Icon  
8/16/2021Sell1,242$25.46$31,621.3267,312View SEC Filing Icon  
See Full Table

Andrea Sabens Buying and Selling Activity at Lantheus

This chart shows Andrea Sabens's buying and selling at Lantheus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lantheus Company Overview

Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
Read More

Today's Range

Now: $61.82
Low: $59.85
High: $62.20

50 Day Range

MA: $71.75
Low: $60.27
High: $90.76

2 Week Range

Now: $61.82
Low: $47.46
High: $100.85


885,790 shs

Average Volume

845,944 shs

Market Capitalization

$4.23 billion

P/E Ratio


Dividend Yield